Back to Search
Start Over
[Chimeric antigen receptor (CAR) T cells targeting CD19 for acute lymphoblastic leukemia].
- Source :
-
[Rinsho ketsueki] The Japanese journal of clinical hematology [Rinsho Ketsueki] 2023; Vol. 64 (9), pp. 1184-1191. - Publication Year :
- 2023
-
Abstract
- Chimeric antigen receptor transgenic T cell (CAR-T) therapy targeting the CD19 antigen was approved for relapsed/refractory acute lymphocytic leukemia in the United States in 2017 and in Japan in 2019. Despite the excellent efficacy of CAR-T therapy, the relapse rate is about 50%. To reduce this rate, it will be important to examine predictive factors for relapse and which patients should receive hematopoietic cell transplantation. In addition, as the high cost of CAR-T cells has become a financial toxicity that threatens the health insurance system in many countries, development of less expensive CAR-T products using non-viral vectors is also underway.
Details
- Language :
- Japanese
- ISSN :
- 0485-1439
- Volume :
- 64
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- [Rinsho ketsueki] The Japanese journal of clinical hematology
- Publication Type :
- Academic Journal
- Accession number :
- 37899199
- Full Text :
- https://doi.org/10.11406/rinketsu.64.1184